ABBV vs BMY
By Alex · Tickerpine
AbbVie Inc. vs Bristol-Myers Squibb Company, side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | ABBV | BMY |
|---|---|---|
| Price | $285.64 | $61.48 |
| Market cap | $504.76B | $125.59B |
| P/E ratio | 80.5 | 13.5 |
| ROE | — | 46.60% |
| Profit margin | 9.80% | 18.87% |
| Revenue growth | 10.20% | 5.70% |
| Dividend yield | 2.42% | 4.10% |
| Beta | 0.23 | 0.18 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
ABBV vs BMY in plain English
- ABBV is the bigger company — about 4.0× the market cap of BMY.
- BMY is cheaper on earnings (P/E 13.5 vs 80.5).
- ABBV is growing revenue faster (10% vs 6%).
- BMY has the higher dividend yield (4.10% vs 2.42%).
How would $1,000 have done in each?
ABBV return calculator
See what $1,000 in AbbVie Inc. would be worth today.
BMY return calculator
See what $1,000 in Bristol-Myers Squibb Company would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.